EXPERIMENTAL AND MOLECULAR MEDICINE, published by SpringerNature, is a premier open-access journal that has been at the forefront of biomedical research since its establishment in 1996. With a focus on innovative studies in biochemistry, molecular biology, and clinical biochemistry, the journal has consistently maintained a distinguished position within the top quartile (Q1) across multiple categories, underscoring its significant impact in these fields. The journal offers researchers and practitioners a platform for high-quality, peer-reviewed articles that advance our understanding of molecular mechanisms underlying health and disease. As a crucial resource for scholars seeking to explore cutting-edge research and practical advancements, its inclusion in relevant databases such as Scopus reflects an exceptional ranking with notable percentiles—placing it among the best in biomedical sciences. With a commitment to open access, EXPERIMENTAL AND MOLECULAR MEDICINE ensures that findings are readily available to the global academic community, facilitating collaboration and innovation in molecular medicine.

Molecular Biomedicine is a prestigious peer-reviewed journal published by SpringerNature, dedicated to advancing the fields of molecular biology and molecular medicine. With a commendable Q1 ranking in both categories for 2023, this journal stands out for its rigorous exploration of the biochemical processes underlying health and disease. Operating out of Germany, Molecular Biomedicine aims to provide comprehensive insights into cutting-edge research, facilitating interdisciplinary collaboration among researchers, healthcare professionals, and students alike. The journal's impact is reflected in its Scopus rankings, placing it in the upper echelons of the fields of biochemistry, genetics, and molecular biology. As an open access platform, it commits to disseminating knowledge widely, ensuring that pivotal discoveries are accessible to all. Researchers looking to publish in a dynamic environment that prioritizes innovation and application in the biomedical sciences will find Molecular Biomedicine an ideal outlet for their work.

EMBO Molecular Medicine, published by WILEY, stands as a premier forum within the field of molecular medicine, advancing scholarly dialogue and research since its launch in 2009. With an impressive impact factor reflected in its Q1 categorization and ranking as the 12th journal in the discipline of Molecular Medicine by Scopus, it serves as a vital resource for researchers, professionals, and students alike. Operating under an Open Access model, EMBO Molecular Medicine ensures that cutting-edge research is freely accessible, fostering greater collaboration and innovation among the global scientific community. Located in the United Kingdom, the journal encompasses a broad scope, featuring high-quality studies that bridge the gaps between basic molecular biology and clinical applications, making significant impacts on health and disease. With a commitment to excellence and a continuously evolving repertoire of research, this journal play a crucial role in shaping the future of biomedical research and therapy.

INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, published by Wiley, is a leading peer-reviewed journal dedicated to the field of experimental pathology. With an ISSN of 0959-9673 and E-ISSN 1365-2613, the journal has been a vital resource for researchers and professionals since its inception in 1990, covering a broad spectrum of topics within pathology, cell biology, and molecular biology. The journal's relevancy is underscored by its Q2 ranking in Pathology and Forensic Medicine and Q3 rankings in both Cell Biology and Molecular Biology, as of 2023, reflecting its significant contribution to the scientific community. Although it does not currently offer open access options, readers can benefit from its insightful research articles and reviews that guide advancements in diagnostic pathology and therapeutic strategies. As the journal continues to evolve, it remains committed to facilitating the exchange of innovative ideas and findings that drive progress in experimental pathology and related fields, making it an indispensable platform for scientists, clinicians, and students alike.

Organogenesis is a leading journal published by Taylor & Francis Inc, dedicated to advancing the field of developmental biology and regenerative medicine. With an ISSN of 1547-6278 and E-ISSN 1555-8592, this journal spans an extensive research scope that includes embryology, transplantation, and biomedical engineering, distinguishing itself as a crucial platform for researchers and practitioners alike. Its impact is reflected in its performance across various categories in 2023, earning Q3 rankings in Biomedical Engineering and Embryology, Q4 in Developmental Biology, and Q2 in Transplantation, showcasing its reputable standing among peer journals. Moreover, with Scopus rankings indicating strong positioning in the fields of medicine and biochemistry, Organogenesis is essential for those looking to publish or stay updated on pioneering research. The journal facilitates rigorous peer-review and offers a forum for disseminating innovative findings, making it an invaluable resource for academics, professionals, and students committed to understanding the complexities of organism development.

Biomolecules & Therapeutics is a prominent journal published by the Korean Society of Applied Pharmacology, dedicated to advancing knowledge in the fields of Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With an ISSN of 1976-9148 and an E-ISSN of 2005-4483, this journal serves as a vital platform for researchers and professionals to disseminate their findings from 2008 through 2024. Ranking in the Q2 category across multiple relevant fields, including Pharmacology and Drug Discovery, and consistently placing in the 60th to 70th percentiles in Scopus rankings, Biomolecules & Therapeutics exemplifies a commitment to high-quality research and scientific integrity. Although it operates on a traditional access model, readers can be assured of the journal's rigorous peer-review process, ensuring that published articles contribute meaningfully to ongoing discourse in pharmacological and biochemical research. Located in Seoul, South Korea, the journal stands at the forefront of innovation in healthcare, making it an essential resource for academics, students, and industry professionals alike.

Biochemistry Moscow-Supplement Series B-Biomedical Chemistry, published by MAIK NAUKA-INTERPERIODICA, is a pivotal journal in the fields of biochemistry, clinical biochemistry, and molecular medicine. Established in 2008, the journal serves as a vital platform for researchers and professionals seeking to disseminate and access groundbreaking research in the biomedical sciences. With an ISSN of 1990-7508 and an E-ISSN of 1990-7516, the journal has been recognized in the Q4 quartile across various categories as of 2023, highlighting its emerging presence in the academic community despite a competitive landscape. Although currently not available as Open Access, the journal encompasses a broad spectrum of studies, ranging from theoretical analysis to practical applications in biomedical research. The journal's dedicated focus on advancing our understanding of biochemical principles positions it as an essential resource for students and professionals alike, enhancing its significance in the global scientific dialogue.

Protein & Cell, published by Oxford University Press, is a distinguished international journal focusing on cutting-edge research in the fields of biochemistry, biotechnology, cell biology, and drug discovery. This open access journal, active since 2014, is dedicated to disseminating innovative findings that advance our understanding of protein functions and cellular processes, making it an essential resource for researchers, professionals, and students alike. With an impressive 2023 impact factor reflected in its Q1 ranking across multiple categories such as Biochemistry, Drug Discovery, and Cell Biology, 'Protein & Cell' stands at the forefront of scientific research, driving collaboration and discussion in the scientific community. Researchers can access the journal freely online, fostering a global exchange of knowledge and contributing to significant advancements in medicine and biotechnology. Located in the United Kingdom, the journal strives to be a pivotal platform for impactful research that influences future studies and applications.

Cell Reports Medicine, published by Cell Press, represents a pivotal advancement in the open access landscape of biomedical research since its inception in 2020. With a dedicated focus on the intersection of medicine, biochemistry, genetics, and molecular biology, this journal has quickly established itself as a key resource, earning a remarkable Q1 ranking in these fields. Based in the United States, Cell Reports Medicine boasts impressive metrics, ranking #25 out of 636 in General Medicine and #18 out of 221 in Biochemistry, underscoring its influence and reach within the scientific community, with a notable 96th and 92nd percentile respectively. As a fully open access journal, it fosters global dissemination of knowledge, ensuring that groundbreaking research is readily available to researchers, professionals, and students alike. The journal not only promotes high-quality research but also aims to bridge the gap between molecular discoveries and clinical applications, making it an essential addition to any academic library or researcher's toolkit.

Biomed Research International is a prominent open access journal published by HINDAWI LTD, dedicated to advancing the field of biomedical research. With its ISSN 2314-6133 and E-ISSN 2314-6141, this journal has been a significant contributor to the scientific community since its inception in 2013, making scholarly work accessible to a global audience. The journal's scope encompasses a range of disciplines, including biochemistry, genetics, molecular biology, immunology, microbiology, and medicine, reflecting its commitment to interdisciplinary research. Ranked in the Q2 quartile as of 2023 across several relevant categories, Biomed Research International is recognized for its high-quality publications that foster innovation and collaboration in biomedical studies. Researchers, professionals, and students looking to share and gain insights into cutting-edge biomedical discoveries will find this journal an essential resource. With a focus on rapid dissemination of research findings, the journal serves as a vital platform for academics to engage with contemporary issues in health and disease, ultimately contributing to the advancement of medical science.